Contribution of the IL-17 Pathway to Psoriasis and Psoriatic Arthritis

被引:0
作者
L. E. Durham
B. W. Kirkham
L. S. Taams
机构
[1] King’s College London,Centre for Molecular and Cellular Biology of Inflammation (CMCBI), Division of Immunology, Infection and Inflammatory Disease
[2] Guy’s and St Thomas’ NHS Trust,Department of Rheumatology
来源
Current Rheumatology Reports | 2015年 / 17卷
关键词
Psoriasis; Psoriatic arthritis; Spondyloarthritis; Interleukin-17; Interleukin-23; Th17 cells; Tc17 cells; IL-17 blockade; Brodalumab; Ixekizumab; Secukinumab; Ustekinumab; CD8+ T Cells; CD4+ T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Investigators have accrued compelling evidence that the IL-17 pathway is central to the pathogenesis of psoriasis and psoriatic arthritis. The evidence comprises genome-wide association studies (GWAS), data from experimental murine models and findings from in vitro studies on patients’ cells or tissue biopsies. More recently, the success of drugs blocking the IL-17 pathway in treating both psoriasis (PsO) and psoriatic arthritis (PsA) confirms that IL-17 is a clinically relevant therapeutic target. However, there remain many unanswered questions: is PsA simply an extension of PsO from the skin to the synovial tissue or are there differences in the underlying pathogenesis of these diseases? Which cell type represents the primary source of IL-17 in PsO and PsA? And how are these cells regulated? This review outlines the IL-17 pathway, summarises the evidence supporting its role in PsO and PsA and discusses recent data that may help to address these yet unresolved questions.
引用
收藏
相关论文
共 98 条
[51]  
Murphy CA(2009)Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells J Invest Dermatol 129 1022-10 e1-306
[52]  
Nakae S(2009)Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes J Allergy Clin Immunol 124 2876-56
[53]  
Ruutu M(2010)Role of Th17 cells in human autoimmune arthritis Arthritis Rheum 62 1190-36
[54]  
Benham H(2012)Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis N Engl J Med 366 2295-9
[55]  
Lories RJ(2014)Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis N Engl J Med 370 349-86
[56]  
Jacques P(2014)Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial Ann Rheum Dis 73 3828-8
[57]  
Nograles KE(2014)Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody J Immunol 192 1914-9
[58]  
Liang SC(2002)The T cell receptor repertoire in psoriatic synovitis is restricted and T lymphocytes expressing the same TCR are present in joint and skin lesions J Rheumatol 29 2878-60
[59]  
Raychaudhuri SP(2001)Psoriatic arthritis joint fluids are characterised by CD8 and CD4 T cell clonal expansions appear antigen driven J Immunol 166 470-6
[60]  
Raychaudhuri SK(2010)HIV-associated psoriasis: pathogenesis, clinical features, and management Lancet Infect Dis 10 33-84